Skip to content
Pioneering the detection of early cancer.
Jun 29, 2022

Harbinger Health and Sarah Cannon Research Institute Launch Clinical Study to Validate and Advance Development of Harbinger’s Novel Early Cancer Detection Platform

Harbinger Health, a biotechnology company pioneering the detection of early cancer, and Sarah Cannon Research Institute (SCRI) announced today the initiation of a 10,000-participant clinical study designed to validate and further develop Harbinger’s novel platform technology for blood-based early cancer detection.

Read More